Prafull S. Gandhi

Scientific Director
Hemab Therapeutics

Presentation(s):

• PB0719 - The novel bispecific antibody HMB-001 enhances the haemostatic response in models of Glanzmann Thrombasthenia by targeting FVIIa to activated platelets

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 78.3 - HMB-001 – a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets for subcutaneous prophylaxis in multiple bleeding disorders including Glanzmann Thrombasthenia

  Wednesday, July 13, 2022
  10:45 AM – 11:00 AM